Zydus Lifesciences is in focus after receiving USFDA clearance with zero observations for its Ahmedabad facility and launching ANYRA, India’s first indigenous Aflibercept biosimilar. The developments strengthen its regulatory standing and expand its ophthalmology portfolio, positioning the company to tap into a large and growing domestic market for retinal therapies.
